Tumor necrosis factor (TNF) stimulates the production of nerve growth factor in fibroblasts via the 55-kDa type 1 TNF receptor  by Hattori, Akira et al.
FEBS 16573 
Tumor 
FEBS Letters 379 (1996) 1577160 
necrosis factor (TNF) stimulates the production of nerve growth 
factor in fibroblasts via the 55kDa type 1 TNF receptor 
Akira HattorPb, Kyozo Hayashib, Michiaki Kohnoa,* 
“Department of Biology, Gifu Pharmaceutical University, 5-6-1, Mitahora-higashi, Gifu 502. Japan 
bDepartment of Molecular Biology, G~jii Pharmaceutical University, 5-6-1, Mitahora-higashi, Gifu 502, Japan 
Received 8 December 1995; revised version received 13 December 1995 
Abstract The role of the two types of tumor necrosis factor 
(TNF) receptors, TNF-Rl and TNF-R2, in mediating the capac- 
ity of TNF to stimulate nerve growth factor (NGF) production 
in fibroblasts has been investigated. Although Swiss 3T3 cells 
express both the TNF-Rl and TNF-R2, an agonistic anti-TNF 
Rl antibody, but not an agonistic anti-TNF-R2 antibody, in- 
creases the NGF mRNA level and stimulates the production of 
NGF protein in the cells. Treatment of the cells with a combina- 
tion of anti-TNF-R2 antibody and interleukin-lfl (IL-1jI) does 
not increase the NGF production induced by IL-l/3 alone, al- 
though TNF’s activity to stimulate NGF production is markedly 
enhanced by IL-l/K Furthermore, simultaneous addition of the 
both antibodies does not increase the NGF production above that 
observed with the anti-TNF-Rl antibody, indicating that TNF- 
Rl alone mediates the TNF’s activity to stimulate NGF produc- 
tion in fibroblasts. 
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1. Introduction 
Tumor necrosis factor-a (TNF), a macrophagelmonocyte- 
derived cytokine, was originally identified as a factor with anti- 
tumor activity in vitro and in vivo, but is now known to be 
implicated in a wide range of biological processes including 
inflammation, immunoregulation, antiviral defense, endotoxic 
shock, cachexia, angiogenesis, and mitogenesis [l-3]. We have 
recently shown that TNF is also involved in modulating neu- 
ronal cell function through an indirect mechanism by which it 
stimulates the synthesis and secretion of NGF in fibroblasts 
and glial cells [4]. 
TNF exerts its diverse effects through two distinct cell sur- 
face binding sites, the type 1 TNF receptor (TNF-Rl, -55-kDa 
in size) and the type 2 TNF receptor (TNF-R2, -75-kDa) [5,6]. 
These two types of receptors bind TNF with high affinity but 
differ in their intracellular domains and thus initiate distinct 
signaling pathways that result in the induction of different 
cellular responses [7]. A number of studies have investigated the 
importance of each of the two TNF receptors in signaling the 
different activities of TNF. Several polyclonal and monoclonal 
antibodies directed against human and mouse TNF-R l/TNF- 
R2 have been shown to behave as receptor agonists and to elicit 
the biological activities of TNF. Analysis of the results obtained 
using these antibodies has indicated that TNF-Rl is implicated 
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in eliciting the major effects of TNF such as cytotoxicity, 
fibroblasts proliferation, and induction of protective activity 
[&lo], whereas TNF-R2 initiates signals for thymocyte and 
cytotoxic T cell proliferation [1 11. On the other hand, several 
reports have suggested that there is a redundancy in the func- 
tion of these two types of receptors [ 12,131. In this study, we 
have investigated whether TNF-Rl or TNF-R2, or both are 
involved in mediating a newly described activity of TNF that 
stimulates NGF production in fibroblasts. 
2. Materials and methods 
2.1. Materials 
Recombinant murine TNF-a (muTNF), the agonistic polyclonal 
anti-muTNF-Rl antibody (lot. 12571-38B) [l I], and the agonistic poly- 
clonal anti-muTNF-R2 antibody (lot. 12074-26B) [l l] were kindly pro- 
vided by the Genentech, Inc. manufacturing group (South San Fran- 
cisco, CA). Recombinant human TNF-a (hTNF) was a kind gift from 
Dr. M. Tsujimoto (Suntory Institute for Biomedical Research, Osaka). 
Recombinant human IL-lp was purchased from Toyobo (Osaka), and 
recombinant murine interferon-y (IFN-y) was from Genzyme (Cam- 
bridge). Other chemicals and reagents were of the purest grade available. 
2.2. Cell culture 
Swiss albino mouse fibroblasts (Swiss 3T3; American Type Culture 
Collection, CCL92) were obtained through the Japanese Cancer Re- 
search Resources Bank. Subconfluent cultures of Swiss 3T3 cells in 
Dulbecco’s modified Eagle’s medium (DMEM) containing 10% calf 
serum were rendered quiescent by incubation in serum-free medium 
(DMEM containing 5 mg/ml of bovine serum albumin, 1 pg/ml insulin, 
2 &ml transferrin, 20 nM Na,SeO,, and 10 mM HEPES, pH 7.4) for 
24 h; TNF, other cytokines, or the anti-TNF receptor antibodies were 
then added [4,14]. 
2.3. Two-site enzyme-linked immunosorbent assay of NGF 
The NGF level in the conditioned media of Swiss 3T3 cells, treated 
with cytokines or the anti-TNF receptor antibodies, was assayed by the 
two-site enzyme-linked immunosorbent assay (ELISA) specific for 
murine submaxillary gland B-NGF as described previously [4,14]. 
2.4. RNA isolation and Northern blot analysis 
Total RNA was isolated from anti-TNF receptor antibodies/cyto- 
kines-stimulated Swiss 3T3 cells according to the method of 
Chomczynski and Sacchi [15]. Twenty pg of total RNA was fraction- 
ated on 1.2% agarose gels containing 2.2 M formaldehyde and then 
transferred to a Zeta-probe membrane (Bio-Rad). The filter-bound 
RNA was hybridized with the randomly primed, ‘*P-labeled mouse 
/I-NGF cDNA probe [4] for 16 h at 42°C then the filters were washed 
under stringent conditions following the instruction manual (Bio-Rad). 
2.5. Iodination of muTNF and binding assay 
Recombinant muTNF was radioiodinated by using the Bolton and 
Hunter reagent as described previously [16]. The specific radioactivity 
of the ‘251-labeled muTNF was 4.17 x 10’ cpm/pg. Binding of lz51- 
labeled muTNF to Swiss 3T3 cells was performed as described [16] with 
slight modification. Briefly, Swiss 3T3 cells were seeded at 5 x lo5 cells/ 
well in 6-cm dishes and allowed to growth for 24 h. Cells were then 
incubated in binding buffer (DMEM containing 10% calf serum and 
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Fig. 1. Binding of ‘251-labeled muTNF to Swiss 3T3 cells. Increasing concentrations of ‘2SI-labeled muTNF were incubated with 6 x lo5 Swiss 3T3 
cells for 2 h at room temperature, and the cell associated radioactivity was determined (total binding). The specific binding activity of the receptors 
(total binding minus nonspecific binding) for ‘251-labeled muTNF was the binding activity observed in the presence of a 200-fold excess of unlabeled 
muTNF or hTNF. When unlabeled muTNF was employed, the binding activity was considered to be due to the sum of TNF-RI and TNF-R2 specific 
binding activity (m). When unlabeled hTNF was used, the binding activity was considered to be due solely to TNF-RI (0). The difference between 
the two specific binding activities gave the TNF-R2 specific binding activity (0) (left). The data are also presented in Scatchard plots (right). Two 
independent experime& yielded similar results. 
25 mM HEPES, pH 7.4) containing 0.30-30 @ml of [‘251]muTNF for 
2 h at room temperature on a rocker platform. After washing with the 
binding buffer, the cells were solubilized with 0.75 ml of solubilization 
buffer (1% Triton X-100, 10% glycerol, 20 mM HEPES, pH 7.5,0.05% 
bovine serum albumin) for 20 min at 37°C. Radioactivity was deter- 
mined in aliquots (0.6 ml) in a Packard gamma counter. Nonspecific 
binding was determined by using a 200-fold excess of unlabeled 
muTNF or hTNF. The number of cells in replicate wells was deter- 
mined by counting in a hematocytometer. Each data point was deter- 
mined in triplicate, and binding data were analyzed according to the 
method of Scatchard [17]. 
3. Results 
3.1. Swiss 3T3 cells express both the 55kDa type 1 TNF 
receptor and the 7.5kDa type 2 TNF receptor 
Human TNF can bind murine 55kDa type 1 TNF receptor 
(TNF-Rl) but not murine 75kDa type 2 TNF receptor (TNF- 
R2), whereas murine TNF binds both TNF-Rl and TNF-R2 
[ 181. We utilized this TNF species specificity to analyze the 
expression of TNF receptors on Swiss 3T3 cells. Thus, the 
specific binding (total binding minus nonspecific binding) of 
[‘*‘I]muTNF to Swiss 3T3 cells observed in the presence of a 
200-fold excess of unlabeled muTNF was considered to be the 
sum of specific binding to TNF-Rl and TNF-R2, while the 
specific binding observed using a 200-fold excess of unlabeled 
hTNF was considered to be that due to only TNF-Rl. 
Radiolabeled muTNF specifically bound to Swiss cells in a 
dose-dependent manner; a typical set of specific binding curves 
and corresponding Scatchard analyses are shown in Fig. 1. 
These results clearly showed that the Swiss 3T3 cells expressed 
both the TNF-Rl (870 receptors/cell with a dissociation con- 
stant of 95 PM) and TNF-R2 (210 receptors/cell with a dissoci- 
ation constant of 200 PM). The expression of both types of the 
TNF receptors on Swiss 3T3 cells was also shown by FACS 
analysis using agonistic polyclonal anti-muTNF-RI and anti- 
muTNF-R2 antibodies which were identical to those used in the 
experiments described below (data not shown). 
3.2. An agonistic anti-muTNF-RI antibody, but not an agonistic 
anti-muTNF-R2 antibody, stimulates theproduction of NGF 
in Swiss 3T3 cells 
Both hTNF and muTNF were found to stimulate the pro- 
duction of NGF in Swiss 3T3 cells, when analyzed by the 
two-site ELISA for the murine submaxillary gland B-NGF [4]. 
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Fig. 2. Dose-responses of anti-muTNF-Rl and anti-muTNF-R2 anti- 
bodies to stimulate NGF production in Swiss 3T3 cells. Swiss 3T3 cells 
were cultured for 48 h with varying dose of anti-muTNF-Rl antibody, 
anti-muTNF-R2 antibody, or both antibodies in combination. The cells 
were also treated with hTNF (30 rig/ml), muTNF (30 ng/ml), or the 
combination of hTNF (30 &ml) and anti-muTNF-R2 antibody (35 
pug/ml). The NGF level in the culture media was assayed by the two-site 
ELISA system. Means + S.E. of 8 determinations using two 3.5-cm 
dishes for each experimental condition are indicated. Results shown are 
representative of three experiments that gave essentially the same re- 
sults. 
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However, muTNF was more effective than hTNF when the 
cells were treated at the maximally effective concentration (30 
nglml) (Fig. 2). These results suggested that the stimulatory 
effect of TNF on NGF production in Swiss 3T3 cells might be 
mediated through the activation of both TNF-Rl and TNF- 
R2, since muTNF can bind to both the muTNF-Rl and 
muTNF-R2, whereas hTNF binds only to muTNF-Rl [ 181. To 
examine more directly this point, we stimulated the cells with 
agonistic antibodies directed against muTNF-Rl and muTNF- 
R2 [ll]. 
Treatment of Swiss 3T3 cells with an agonistic anti-muTNF- 
Rl antibody increased the level of a transcript migrating at 
about 1.3 kilobases (Fig. 3), which is consistent in size with the 
NGF mRNA detected in murine submaxillary glands [ 191. The 
increase in the NGF mRNA level was observed after 3 h, and 
became maximal within 12 h of incubation with the antibody. 
This result is essentially identical to that observed in hTNF- 
stimulated Swiss 3T3 cells [4]. On the other hand, treatment of 
Swiss 3T3 cells with an agonistic anti-muTNF-R2 antibody did 
not increase the NGF mRNA level at all. Furthermore, the 
NGF mRNA level in Swiss 3T3 cells stimulated with both 
receptor antibodies or a combination of the anti-muTNF-R2 
antibody and hTNF was essentially identical to that in the cells 
treated with the anti-muTNF-Rl antibody or hTNF alone 
(data not shown). 
The anti-muTNF-Rl antibody also stimulated the produc- 
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Fig. 3. Northern blot analysis. Total RNA (20 pg) was extracted from 
Swiss 3T3 cells that had been treated for varying times with the anti- 
muTNF-Rl antibody (35 pg/ml), anti-muTNF-R2 antibody (35&ml), 
IL- lj3 (3 &ml), or combinations of these agents. The RNA was electro- 
phoretically resolved in a 1.2% agaroselformaldehyde gel, blotted, and 
hybridized with “P-labeled mouse b-NGF cDNA probe, and, after 
stripping, with a /3-actin probe. Blots were quantitated with a FUJIX 
Bio-imaging analyzer BAS 1500, and -fold induction of NGF mRNA 
normalized to /I-actin mRNA is indicated. Position of 18s rRNA is 
indicated. Results shown are representative of three similar experi- 
ments. 
Fig. 4. Stimulation of NGF production in Swiss 3T3 cells with combi- 
nations of anti-muTNF Rl/R2 antibodies and various cytokines. The 
NGF level in the culture medium of Swiss 3T3 cells treated for 48 h with 
hTNF (30 ng/ml), anti-muTNF Rl antibody (35 pg/ml), anti-muTNF 
R2 antibody (35 @ml), IL-l/I (3 ng/ml), or IFN-r (30 U/ml), separately 
or in combination, was assayed by the two-site ELISA system as de- 
scribed in the legend of Fig. 2. Results shown are representative of two 
independent experiments. 
tion of NGF protein in Swiss 3T3 cells. As shown in Fig. 2, the 
response was dose-dependent, and the amount of NGF pro- 
duced by the cells stimulated with 35 pg/rnl of anti-muTNF-Rl 
antibody was essentially identical with that produced by the 
cells stimulated with the maximally effective concentration (30 
&ml) of hTNF. On the contrary, the anti-muTNF-R2 anti- 
body did not stimulate the production of NGF in Swiss 3T3 
cells up to concentration of 35 fig/ml, and furthermore, treat- 
ment of the cells with both receptor antibodies or a combina- 
tion of anti-muTNF-R2 antibody and hTNF did not increase 
the amount of NGF compared to cells stimulated with the 
anti-muTNF-Rl antibody or hTNF alone. 
We have recently shown that the stimulatory activity of TNF 
on NGF production in fibroblasts is markedly synergized by 
IL-la//I and IFN-y [14]. Likewise, stimulation of Swiss 3T3 
cells with combinations of anti-muTNF-Rl antibody and IL- 
lp/IFN-y apparently increased the NGF mRNA level and also 
stimulated the NGF production in the cells to a much greater 
degree than did each agent alone (Figs. 3 and 4). However, the 
simultaneous addition of anti-muTNF-R2 antibody and IL-l/I 
or IFN-y did not increase the NGF production above the level 
induced by IL-l/I or IFN-y alone. 
4. Discussion 
The present studies have clearly demonstrated that TNF-Rl 
is involved in mediating the recently described activity of TNF 
that stimulates NGF production in fibroblasts [4]. Although 
Swiss 3T3 cells express both TNF-Rl and TNF-R2, an agonis- 
tic anti-muTNF-R2 antibody did not stimulate the production 
of NGF in these cells up to a concentration of 35 pg/ml. Stim- 
ulation of Swiss 3T3 cells with a combination of anti-muTNF- 
R2 antibody and IL-1 j? or IFN-y did not increase the NGF 
production induced by IL-l/3 or IFN-y alone, even though 
TNF’s activity to stimulate NGF production is markedly en- 
hanced by IL-l a/p and IFN-y [14]. Furthermore, the simulta- 
neous addition of both antibodies or anti-muTNF-R2 antibody 
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and hTNF did not increase the production of NGF above that 
observed with the anti-muTNF-RI antibody or hTNF alone. 
These results indicate that TNF-Rl alone mediates the 
TNF’s activity to stimulate NGF production in Swiss 3T3 cells. 
However, muTNF (which has access to both muTNF-RI and 
muTNF-R2) was slightly more effective than hTNF and anti- 
muTNF-R 1 antibody (which binds only to muTNF-R 1) for the 
stimulation of NGF production. A similar higher efficacy of 
muTNF compared to hTNF in stimulating the production of 
IL-6 and granulocyte macrophage-colony stimulating factor in 
mouse fibroblasts has been recently reported [20]. A combina- 
tion of anti-muTNF-R2 antibody with anti-muTNF-Rl anti- 
body or hTNF did not show any increased activity compared 
to anti-muTNF-Rl antibody or hTNF alone, suggesting that 
TNF-R2 by itself does not generate signals which potentiate 
TNF activity. Rather, TNF-R2 contributes to elicit the maxi- 
mal activity of TNF through an indirect mechanism that facil- 
itates the association of TNF with TNF-R 1 which is the recep- 
tor responsible for all signal generation. The possible utilization 
of such a ‘ligand passing’ mechanism by TNF-R2 has recently 
been proposed [21]. 
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